CRISPR genome-wide screening identifies PAK1 as a critical driver of ARSI cross-resistance in prostate cancer progression.
Chen H, Dong K, Ding J, Xia J, Qu F, Lan F, Liao H, Qian Y, Huang J, Xu Z, Gu Z, Shi B, Yu M, Cui X, Yu Y.
Chen H, et al. Among authors: yu m, yu y.
Cancer Lett. 2024 Apr 10;587:216725. doi: 10.1016/j.canlet.2024.216725. Epub 2024 Feb 15.
Cancer Lett. 2024.
PMID: 38364963